BCL2 and breast carcinoma: Cittelly et al demonstrated that breast cancer overexpressing HER-2 exhibited resistance to tamoxifen through the upregulation of B-cell CLL/lymphoma 2 (BCL-2) and the suppression of miR-15a/16 induced by tamoxifen (10).